Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling

Zhipeng Su1,2, Shengnan Han2,3, Qiumei Jin2, Ningning Zhou2, Junwan Lu2, Fugen Shangguan2, Shiyi Yu2, Yongzhang Liu2, Lu Wang2, Jianglong Lu1, Qin Li1, Lin Cai1, Chengde Wang1, Xiaohe Tian4, Lingyan Chen2, Weiming Zheng1 and Bin Lu2

Abstract

Ciclopirox (CPX) is an antifungal drug that has recently been reported to act as a potential anticancer drug. However, the effects and underlying molecular mechanisms of CPX on glioblastoma multiforme (GBM) remain unknown. Bortezomib (BTZ) is the first proteasome inhibitor-based anticancer drug approved to treat multiple myeloma and mantle cell lymphoma, as BTZ exhibits toxic effects on diverse tumor cells. Herein, we show that CPX displays strong anti-tumorigenic activity on GBM. Mechanistically, CPX inhibits GBM cellular migration and invasion by reducing N-Cadherin, MMP9 and Snail expression. Further analysis revealed that CPX suppresses the expression of several key subunits of mitochondrial enzyme complex, thus leading to the disruption of mitochondrial oxidative phosphorylation (OXPHOS) in GBM cells. In combination with BTZ, CPX promotes apoptosis in GBM cells through the induction of reactive oxygen species (ROS)-mediated c-Jun N-terminal kinase (JNK/p38 mitogen-activated protein kinase (MAPK) signaling. Moreover, CPX and BTZ synergistically activates nuclear factor kappa B (NF-κB) signaling and induces cellular senescence. Our findings suggest that a combination of CPX and BTZ may serve as a novel therapeutic strategy to enhance the anticancer activity of CPX against GBM.

Introduction

Ciclopirox (CPX), 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one, is a synthetic hydroxyypyridone derivative1. As Batrafen, Loprox, or Penlac, CPX olamine is currently used topically to treat fungal infections of the skin1. CPX is an iron chelator that forms complexes with trivalent metal cations such as Fe3+, leading to the inhibition of metal-dependent enzymatic activity, including that of peroxidase. Intracellularly, peroxidase plays a protective role in the decomposition of H2O2 and the reduction of organic peroxides2. CPX can induce cell death in a variety of cancers3–6; for example, CPX inhibits cell death in a variety of cancers3–6; for example, CPX inhibits tumor growth in xenografts of the human breast cancer cell line, MDA-MB2313. Our previous study reported that CPX can activate PERK-dependent endoplasmic reticulum (ER) stress to induce cell death and overcome chemoresistance in colorectal cancer cells7. In a phase I clinical trial, CPX showed efficacy and tolerability in the treatment of patients with relapsed or refractory hematologic malignancies8. However, the roles and underlying mechanisms...
of CPX in glioblastoma multiforme (GBM) remain unknown.

Bortezomib (BTZ, Velcade) is the first proteasome inhibitor-based anticancer drug approved by the US FDA to treat multiple myeloma and mantle cell lymphoma. Phase I clinical trials showed that BTZ can be used as a chemosensitizer in refractory and relapsed acute lymphoblastic leukemia. Subsequent phase I and phase II clinical trials for the treatment of childhood leukemia and lymphoma demonstrated that BTZ can restore the chemosensitivity of leukemia cells to conventional drugs. In addition, more than 40 early clinical trials, comprising approximately two dozen targeted small molecules and BTZ, are currently being evaluated. Mechanistically, BTZ may inhibit the activation of nuclear factor kappa B (NF-κB) signaling by regulating the stabilization of IκBα in T-cell acute lymphoblastic leukemia. In contrast, the activation of NF-κB is associated with temozolomide (TMZ)-induced senescence in GBM cells.

GBM is highly invasive and often infiltrates surrounding normal brain tissue, making it almost impossible to completely remove the tumor. In the present study, we investigated whether BTZ can increase the sensitivity of GBM to CPX and evaluated the synergistic effects of CPX and BTZ in GBM cells. We demonstrated in GBM cells that CPX blunted expressions of N-Cadherin, MMP9 and Snail, which subsequently led to inhibition of the cell migration and invasion. We further revealed that CPX impaired mitochondrial oxidative phosphorylation (OXPHOS) through inhibiting key subunits of the mitochondrial electron transport chain enzyme complexes, and thereby suppressed cell growth and induced apoptosis. Importantly, we uncover a novel molecular mechanism by which CPX combined with BTZ exhibited synergistic effects in promoting GBM cellular death and senescence by simultaneously enhancing the activation of reactive oxygen species (ROS)-mediated JNK/p38 MAPK and NF-κB pathways. Our findings provide a potential novel strategy for the use of CPX and BTZ to improve the survival of GBM patients, as well as to reduce the cost of treatments.

Materials and methods

Cell culture

Human glioblastoma cell lines U251, SF126, A172, and U118 were obtained from the Cell Bank of Shanghai Institute of Cell Biology (Shanghai, China) and maintained in high-glucose DMEM (Dulbecco’s Modified Eagle Medium) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, NY, USA) and 1% penicillin/streptomycin. Cells were incubated at 37 °C in a humidified incubator with 5% CO2. After colonies became visible, the medium was replaced with fresh DMEM containing vehicle (DMSO), CPX, BTZ, or a combination of CPX and BTZ. Cells were incubated for another 5–7 days and then fixed with methanol for 20 min at room temperature. Colonies were stained with 0.1% crystal violet for 20 min at room temperature and imaged and quantified using ImageJ cell viability and proliferation assays

Cells were seeded in 96-well plates at a density of 5 × 103 cells per well and the indicated concentrations (DMSO, 5, 10, 20, 40, 80, 160, and 320 μM) of CPX were added on the next day for another 48 h. Cell viability was measured by MTT cell proliferation and cytotoxicity kits according to the manufacturer’s instructions. For proliferation assays, cells were seeded in 96-well plates at a density of 3 × 103 cells per well and treated on the next day with a various concentrations (20, 40, and 80 μM for U251 cells; 10, 20, and 40 μM for SF126 cells) of CPX or vehicle (DMSO) alone for 0, 1, 2, 3, and 4 days. The proliferation of GBM cell proliferation was measured using MTT assays.

Colonies formation assay

Colonies formation assay is widely used to test the ability of a single cell to grow into a colony, which enables us to predict tumor cell sensitivity to cytostatic drugs. We performed the colony formation assay as described previously. Briefly, GBM cells were seeded at a density of 1 × 103 cells per well into six-well plates and were cultured at 37 °C in a humidified incubator with 5% CO2. After colonies became visible, the medium was replaced with fresh DMEM containing vehicle (DMSO), CPX, BTZ, or a combination of CPX and BTZ. Cells were incubated for another 5–7 days and then fixed with methanol for 20 min at room temperature. Colonies were stained with 0.1% crystal violet for 20 min at room temperature and imaged and quantified using ImageJ.
software. The BTZ concentration used (24 nM) was based on the published work by Comba A and Vlachostergios PJ18,19.

Transwell cell migration and invasion assays
Cell migration and invasion were analyzed using a Transwell assay (24-well plates; 8-μm pore-size insert; Corning Inc., ME, USA) as described17. Cultures were treated with CPX for 48 h. Migrated cells were stained with 0.1% crystal violet then imaged and quantified.

RNA preparation and quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted from cultured cells or tissue samples using Trizol reagent (ThermoFischer, NY, USA) following the manufacturer’s protocol. qRT-PCR was carried out as described previously20. Primer sequences used for qRT-PCR are listed in Supplementary Table S1.

Isolation of cytoplasmic, nuclear, and mitochondrial fractions
The Nuclear and Cytoplasmic Protein Extraction Kit and Cell Mitochondria Isolation Kit (Beyotime Biotechnology, Shanghai, China) were used to separate cytosolic, mitochondrial, and nuclear fractions according to the manufacturer’s protocols.

Protein extraction and immunoblot analysis
Total proteins from lysed cells or tumor tissues were extracted using RIPA buffer (50 mM Tris-HCl, pH 7.4, 1.0% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl) containing protease and phosphatase inhibitors (1 mM NaF and 1 mM Na3VO4) on ice. Samples were centrifuged at 12,000 g for 20 min at 4 °C, after which the supernatants were collected. Protein concentrations were determined using the Pierce BCA protein assay kit, and immunoblot analysis was performed using a standard protocol as described previously20. Optical densities of protein bands were determined using ImageJ. The details of the primary antibodies are provided in Supplementary Table S2.

Oxidative phosphorylation assay
Measurements of intact cellular oxygen consumption rates (OCRs) of A172, U118, U251, and SF126 cells were performed with a Seahorse XF-96 Extracellular Flux Analyzer (Agilent Technologies Inc., North Billerica, MA), as described20.

Flow cytometry analysis for detection of ROS and apoptosis
For the ROS assay, U251 or U118 cells (1 × 107 cells each) in 100 μl of PBS were subcutaneously injected into the dorsal-left flank of 6-week-old male BALB/c athymic nude mice (SLAC, Shanghai, China). After tumors reached ~300–400 mm³ in volume, mice were randomized into two groups (six mice per group) for treatment with vehicle control (0.9% NaCl) or CPX. The mice were then administered an intraperitoneal injection of CPX (dissolved in 0.9% NaCl, 20 mg/kg for U251 cells and 15 mg/kg for U118 cells) or BTZ (0.4 mg/kg), once a day for 12 days. To study the effects of the combination of CPX and BTZ on GBM cell (U251 and SF126) growth in vivo, the tumor-bearing mice were randomized into four groups (five mice per group) following administration of CPX (5 mg/kg), a combination of CPX (5 mg/kg) and BTZ (0.4 mg/kg), and BTZ (0.4 mg/kg), once a day for 14 days. Tumor growth was monitored every two days by measuring the length (L) and width (W) of the tumor, using a digital caliper, and tumor volume was calculated according to the following formula: volume = 1/2 × L × W². Mouse body weights were also measured every 2 days. All of the mice were sacrificed after 14 days, after which tumors were dissected, imaged, and weighed. The animal experiments were approved by the Institutional Animal Care and Use Committee at the University Laboratory Animal Research of Wenzhou Medical University, and were carried out in accordance with institutional guidelines.

Statistical analysis
Statistical analyses were performed using SPSS Standard version 16.0 (SPSS Inc., IL, USA) and graphs were plotted via GraphPad Prism 5 (GraphPad Software, CA, USA). Statistical differences between two groups were analyzed...
Results
CPX inhibits GBM cell growth in vitro and in vivo
To investigate the effect of CPX on GBM cells in vitro, we first evaluated the cytotoxicity of CPX in a panel of GBM cells (U251, SF126, A172, and U118 cells; Fig. 1A and Supplementary Fig. S1a). The IC_{50} values measured ranged from 34–74 µM. In cell proliferation assays, CPX rapidly suppressed GBM cell growth in culture (Fig. 1B and Supplementary Fig. S1B). In clonogenic assays, CPX significantly inhibited colony formation in GBM cells in a dose-dependent manner (Fig. 1C and Supplementary Fig. S1c).

We used a mouse xenograft model to examine the effect of CPX on GBM cell growth in vivo. CPX dramatically suppressed the growth of U251 and U118 cells tumors as compared to vehicle control in vivo (Fig. 1D, E). Tumor weight decreased significantly in the CPX-treated group (Fig. 1F) without notable loss of body weight (Fig. 1G).

Taken together, these results demonstrate that CPX inhibits GBM cell growth in vivo and in vitro at concentrations exhibiting only minor toxicity.

CPX blocks GBM cellular migration and invasion in vitro
Tumor metastasis and invasion contribute to the high mortality rate and poor prognosis of GBM. To explore the impact of CPX on GBM metastasis, we used transwell assay to evaluate the effect of CPX on cell migration and invasion. Our data show that CPX treatment markedly inhibited migration of U251 and SF126 cells compared to vehicle control in vitro (Fig. 2D). Tumor weight decreased significantly in the CPX-treated group (Fig. 2F) without notable loss of body weight (Fig. 2G).

Taken together, these results demonstrate that CPX inhibits GBM cell growth in vivo and in vitro at concentrations exhibiting only minor toxicity.

CPX impairs mitochondrial respiration and induces ROS production in GBM cells
The majority of cellular energy, namely adenosine triphosphate (ATP), is produced in mitochondria via OXPHOS. Therefore, it is an essential cancer therapeutic strategy to target OXPHOS. To evaluate the effect of CPX on the mitochondrial respiratory chain, we first measured changes in the cellular oxygen consumption rate (OCR) in CPX-treated GBM cells. We observed a significant decrease of overall OCR in a dose-dependent manner in CPX-treated GBM cells (Supplementary Fig. S2a). All three indexes of mitochondrial respiration, basal and maximal respiration and ATP production, were significantly reduced after CPX treatment of GBM cells (Supplementary Fig. S2b–d), suggesting that CPX treatment caused an impairment of mitochondrial OXPHOS. Next, we determined the expression of a variety of subunits of enzymatic complexes of the mitochondrial OXPHOS system in GBM cells (U251 and SF126 cells). Immunoblotting demonstrated that the levels of cytochrome c oxidase (COX) subunits I (COX I), II (COX II), and IV (COX IV) were decreased upon CPX treatment in a dose-dependent manner. However, there was no significant difference in the protein expression of NADH: ubiquinone oxidoreductase subunit A9 (NDUFA9), NADH-ubiquinone oxidoreductase chain 1, succinate dehydrogenase (subunit A), or ATP synthase subunit alpha (Fig. 3A).

Since the majority of intracellular ROS are generated in the mitochondrial respiratory chain, the selective reduction of COX subunits led us to speculate that CPX-induced impairment of mitochondrial function may enhance ROS production. Indeed, mitochondrial ROS (mitoROS) levels were significantly increased upon CPX treatment, and treatment of GBM cells with NAC (a ROS scavenger) dramatically decreased ROS production (Fig. 3B). Moreover, NAC treatment rescued overall OCR reduction by CPX in GBM cells (Fig. 3C), as well as the three indexes of mitochondrial respiration, namely, basal and maximal respiration rate, and ATP production rate (Fig. 3D–F). Collectively, these data indicate that CPX impairs mitochondrial OXPHOS, thus leading to increased production of ROS in GBM cells.

CPX and BTZ synergistically activate JNK/p38 MAPK signaling pathways
BTZ has a cytotoxic effect in a variety of tumor cells and can reduce the therapeutic concentration of tumor necrosis factor-related apoptosis-inducing ligand, for treating GBM. To determine whether BTZ reduces the concentration of CPX required for its effects in GBM cells, we combined BTZ with CPX to treat U251 and SF126 cells. Simultaneous treatment with CPX (20 µM) and BTZ (24 nM) for 24 h repressed the proliferation of GBM cells compared to the effect of CPX or BTZ alone (Fig. 4A and Supplementary Fig. S3) and also synergistically abolished colony formation (Fig. 4B). Correspondingly, both cellular ROS (Fig. 4C) and apoptosis (Fig. 4D, E) were significantly elevated when CPX and BTZ were used in combination. Correspondingly, phosphorylation of both JNK and p38 MAPK, which may be activated by
Fig. 1 CPX suppresses GBM cell growth in vitro and in vivo. A The IC_{50} of U251 and SF126 cells treated with CPX for 48 h was evaluated using MTT cellular proliferation and cytotoxicity assay kits. B Proliferation of U251 and SF126 cells treated with CPX for four days was measured by MTT cellular proliferation and cytotoxicity assay kits. Data represent mean ± SD (n = 3, ***p < 0.001). C Colony formation assays of U251 and SF126 cells treated with or without CPX for 48 h. Representative images of colony formation assays are shown (left panel). Colony number counts (right panel) are presented as the mean ± SD (n = 3, ***p < 0.001). D–G Nude mice bearing U251 and U118 cell tumors (n = 6, each cell line) were injected with either CPX or 0.9% NaCl. After 12 days of once-daily injections, the mice were sacrificed. Representative dissected tumors are shown (D). Tumor volumes were measured at the indicated intervals (E) and dissected tumors were weighted at the end of the 14-day period (F). The body weight of mice treated with CPX or 0.9% NaCl was measured at the indicated intervals. Data represent mean ± SD (n = 6; ***p < 0.001. ns, not significant) (G).
ROS to trigger apoptosis\textsuperscript{23}, was significantly increased by the combination of CPX and BTZ (Fig. 4F). These results suggest that the combination of CPX and BTZ promotes apoptosis of GBM cells by ROS-mediated activation of the JNK/p38 MAPK pathway.

**CPX and BTZ synergistically activate NF-κB signaling pathways**

To further investigate the synergistic effect as well as the molecular mechanism underlying this effect of CPX and BTZ in GBM cells, we examined the expression of NF-κB pathway-related proteins using immunoblotting assays. In the resting state, p65 and IκBs are in the form of inactive dimers in the cytosol. Upon induction by a variety of stimuli, IκBs are degraded and the released NF-κB dimers translocate to the nucleus, upon which NF-κB signaling is activated\textsuperscript{24}. As shown in Fig. 5A, CPX or BTZ treatment increased p-p65 levels in GBM cells, whereas p65 expression was unchanged, and the NF-κB-signaling inhibitory protein, IκBα, decreased. Notably, combined treatment with CPX and BTZ led to a greatly enhanced up-regulation of p-p65 levels and down-regulation of IκBα protein expression in GBM cells (Fig. 5A). Furthermore, combined CPX and BTZ treatment synergistically promoted p65 nuclear translocation as evidenced by immunoblotting (Fig. 5B) and immunofluorescence (Fig. 5C and Supplementary Figs. S4a–d, S5a–d) analyses. Previous studies demonstrated that p65 enters the
nucleus to induce the senescence-associated secretory phenotype (SASP) through regulating the expression of inflammation-related factors including interleukin 6 (IL6) and IL8. Both IL6 and IL8 mRNAs were increased by CPX and BTZ alone, and synergistically by treatment of GBM cells with combined CPX and BTZ (Fig. 5D).

Therefore, we propose that combined CPX and BTZ treatment in GBM cells activates the NF-κB signaling pathway and induces the expression of IL6 and IL8 mRNAs.

Combination of CPX and BTZ inhibits GBM tumor growth in vivo

We used the mouse xenograft model to investigate the inhibitory efficiency of combined CPX and BTZ on the growth of GBM cell tumors in vivo. U251 and SF126 cells
Fig. 4 The combination of CPX and BTZ promotes apoptosis of GBM cells via activating the ROS-mediated JNK/p38 MAPK signaling. A MTT assays of U251 and SF126 cells in response to CPX (20 μM), BTZ (24 nM), or a combination of both drugs for the time indicated. Data represent mean ± SD (n = 3, **p < 0.01; ***p < 0.001). B Colony formation assays of U251 and SF126 cells treated with CPX (20 μM), BTZ (24 nM), or a combination of both drugs. Representative images (upper) and colony numbers (lower) from colony formation assays. Data represent mean ± SD of three independent experiments performed in triplicate (n = 3, **p < 0.01, ***p < 0.001). C U251 and SF126 cells were treated with CPX (20 μM), BTZ (24 nM), or a combination of both drugs, which promoted intracellular ROS production in U251 and SF126 cells measured by a ROS Assay Kit (DCFH-DA). Data are plotted as relative fluorescence intensities and are presented as mean ± SD (n = 3, ***p < 0.001). D, E U251 and SF126 cells were treated with CPX (20 μM), BTZ (24 nM), or a combination of both drugs for 24 h, and apoptosis was determined by flow cytometry. Representative images of apoptosis (D) and results from three independent experiments (E) (**p < 0.01). F Immunoblotting analysis of p38, p-p38, JNK, and p-JNK in U251 and SF126 cells treated with CPX (20 μM), BTZ (24 nM), or a combination of both drugs for 24 h.
were injected subcutaneously into the left flank of BALB/c nude mice (5 weeks old, n = 20). When the tumor volume reached ~100–200 mm³, tumor-bearing nude mice were randomly divided into four groups (receiving saline, CPX, BTZ, or combined CPX/BTZ), with five mice per group. Each mouse received an intraperitoneal injection of saline, or of drug(s) in saline solution, once a day for 14 consecutive days. Measurements of tumor volume (Fig. 6A, B) and weight (Fig. 6C) showed that the drugs reduced GBM cell growth in vivo, and that combined treatment with
CPX and BTZ significantly repressed GBM cell growth in vivo compared to treatment with CPX or BTZ alone. None of the drugs caused obvious toxicity as assessed by body weight of the treated mice (Supplementary Fig. S6a, b). We also evaluated p-p65, IκBα, p-p38 and p-JNK levels in tumor sections via immunoblotting. Consistently, the
combination of CPX and BTZ dramatically activated the JNK/p38 MAPK and NF-κB signaling pathways (Fig. 6D, E, and Supplementary Fig. S7a–d). Collectively, these results indicate that the combined treatment with CPX and BTZ significantly inhibited GBM cell growth in vivo, when compared with control saline or treatment with CPX or BTZ individually.

Discussion

Epithelial–mesenchymal transition (EMT) is essential for cancer cells acquiring aggressive features and thus promoting metastasis and invasion of cancer cells. MMPs, which degrade and modify the extracellular matrix, also play critical roles in EMT to promote cancer metastasis. Accordingly, the present study shows that CPX significantly inhibited GBM cell growth, migration, and invasion via regulating N-Cadherin-Snail-MMP9 signaling pathways in human GBM cell lines. Moreover, we showed that CPX caused mitochondrial dysfunction in GBM cells, and thus leading to mtROS accumulation and GBM cell death. Mitochondria, as the main source of cellular ATP, play an essential role in cellular metabolism, growth, survival, and apoptosis. Mitochondrial dysfunction and ROS are common features of many diseases, including cancer. There is increasing evidence that the majority of ROS production in mitochondria results from electron leakage of mitochondrial complex I and III. These data, as well as the promising anti-GBM effect that we unveiled both in vitro and in vivo, strongly support the view that CPX may serve as a potential therapeutic strategy for GBM.

Preclinical studies have shown that the proteasome inhibitor, MG132, and BTZ can inhibit the proliferation of GBM. In addition, BTZ was found to inhibit DNA repair enzyme O6-methylguanine methyltransferase (MGMT) to overcome MGMT-mediated GBM chemoresistance. The proteasome inhibitor BTZ was also shown to enhance ROS production in mitochondria of various cancer cells and to cause cancer cell apoptosis. Recently, Wagner et al. reported a temporal variations in ROS generation in human glioblastoma T98G cells treated with BTZ. Furthermore, while the EMT markers including Slug, MMP9, MMP2, CD44, N-Cadherin, and vimentin were suppressed by BTZ concomitant increased expression of E-Cadherin was detected in chondrosarcoma cells. In the present study, we investigated whether it is feasible to use a combination of CPX and BTZ at lower doses without affecting their efficacies and, moreover, if such a combination may even synergistically enhance the resultant anti-tumor effects. Interestingly, we found that the proliferation and colony formation of U251 and SF126 cells were significantly inhibited via a CPX/BTZ combination, compared with results of either agent alone. It is well-known that increased intracellular ROS can activate the JNK/p38 MAPK pathway to induce apoptosis. In our present study, we demonstrated that the combined treatment of CPX and BTZ promoted intracellular ROS accumulation and triggered activation of the JNK/p38 MAPK pathway, thereby inducing apoptosis of GBM cells.

NF-κB is a key regulator of diverse cellular processes such as differentiation, proliferation, and immune/inflammatory responses. The mammalian NF-κB family contains five members—p50/p105 (NF-κB1), p52/100 (NF-κB2), p65 (Rel-A), c-Rel, and Rel-B proteins—all of which associate with one another to form active homo- or hetero-dimers. NF-κB dimers form an inactive complex through interaction with IκB and are retained in the cytoplasm of senescent cells, since IκB masks the nuclear localization signal of NF-κB and blocks entry of the latter into the nucleus. Disproportionate activation of NF-κB p65 signaling is closely associated with many chronic diseases, such as inflammatory and autoimmune diseases, and even cancers. Therefore, NF-κB p65 signaling has been a key target for the discovery and development of novel drugs.

The role of NF-κB in tumorigenesis is complex, as in some mouse models the inhibition of NF-κB suppresses, whereas in others it facilitates, tumor development. Previous studies have shown that the proapoptotic effect of BTZ in different cancers may, at least in part, be due to its inhibition of the NF-κB signaling pathway. Bastian et al. have shown that the combination of BTZ and histone deacetylase inhibitors have synergistic activity in preclinical models of B-cell precursor acute lymphoblastic leukemia through activating NF-κB signaling. The activation of NF-κB signaling contributes to the outcome of cancer therapy, especially via mediating chemotherapy-induced senescence. In the present study, we provided evidence that the combination of CPX and BTZ led to the degradation of the NF-κB inhibitor, IκBa, and significantly enhanced activation of NF-κB signaling compared with these effects via CPX or BTZ alone, and dramatically upregulated NF-κB target genes (such as IL-6 and IL-8) in GBM cells. Our data suggest that NF-κB supports senescence by activation of SASP. Further studies are required to elucidate whether CPX/BTZ-induced NF-κB activation represents a feedback of GBM cells to CPX/BTZ treatment.

Despite accumulating evidence for the synergestical effects of BTZ in combination of with several compounds to inhibit GBM cell growth, there is limited understanding on the underlying molecular mechanism. Notably, the combination of BTZ and SR9009, a synthetic pyrrole derivative that act as REV-ERB agonist, exhibits a significant synergetic effect on inhibiting GBM cell growth. Interestingly, Vlachostergios et al found that BTZ may overcome MGMT-related chemoresistance of
GBM cells to TMZ in a schedule-dependent manner through interfering NF-kB, MAPK, STAT3 and HIF-1α signaling pathway. Furthermore, ursodeoxycholic acid, which is an endogenous bile acid existing in human bile, synergizes with BTZ to inhibit GBM progression through promoting ER stress related apoptosis. Here we describe a promising therapeutic combination for treatment of GBM. Our results demonstrate that CPX plays an antitumor role in GBM cells. Moreover, the combined use of CPX and BTZ also synergistically activates the JNK/p38 MAPK pathway to induce apoptosis. CPX/BTZ co-treatment also activated the NF-kB pathway to promote p65 entry into the nucleus, thereby leading to inflammation-associated senescence of GBM cells. Taken together, we propose a mechanistic model of synergistic effects of CPX and BTZ against GBM cells via simultaneously enhancing JNK/p38 MAPK and NF-kB signaling (Fig. 6F). CPX/BTZ co-treatment also activated the NF-kB pathway to promote p65 entry into the nucleus, thereby leading to inflammation-associated senescence of GBM cells. These findings reveal a potentially rapid and cost-effective strategy to re-purpose CPX and BTZ for co-treatment of GBM. Novel drug-delivery strategies may be required to enable CPX and BTZ to bypass the blood-brain barrier, or it may prove possible to deliver CPX and BTZ directly into intracranial tumors. Alternatively, these compounds may serve as leads for development of drugs with superior properties.

Acknowledgements
We thank Prof. Michael Mathews (Rutgers-New Jersey Medical School), Dr. Charles Reichman (Rutgers-New Jersey Medical School) for discussions and critical reading of the manuscript and members of the B. L. Lab for technical support and valuable discussions. This study was supported by grants from National Natural Science Foundation of China (31570772 and 31771534 to B.L.), the Key Scientific and Technological Innovation Projects of Wenzhou (ZY2020017 to B.L), Key Research Project of Traditional Chinese Medicine of Zhejiang Province of China (2019ZD015 to Z.S.), and Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A to B.L.).

Author details
1Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000 Zhejiang, China. 2Protein Quality Control and Diseases Laboratory, Key Laboratory of Medical Genetics of Zhejiang Province, Key Laboratory of Laboratory Medicine, Ministry of Education of China School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035 Zhejiang, China. 3Department of Pathology, The Second Hospital of Jiaxing, Jiaxing University, Jiaxing 314000, China. 4Huai MR Research Center (HMRRC), Department of Radiology, Functional and molecular imaging Key Laboratory of Sichuan Province, West China Hospital of Sichuan University, Chengdu 610041, China

Author contributions
Z.S., SH, QJ, WZ, and BL designed the experiments. ZS, SH, OJ, NZ, JL, FS, SY, JL, LW, JL, QL, LC, CW, XT, and L.C performed experiments. ZS, SH, QJ, JL, YL, XT, WZ, and BL analyzed the data. BL wrote the manuscript with contributions from the other authors. All authors read and approved the final manuscript.

Conflict of interest
The authors declare no competing interests.

Ethics statement
This study did not require ethical approval.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-03535-9.

Received: 5 October 2020 Revised: 14 February 2021 Accepted: 17 February 2021
Published online: 05 March 2021

References
1. Gupta, A. K. & Skinner, A. R. Ciclopirox for the treatment of superficial fungal infections: a review. Int. J. Dermatol. 42 Suppl 1, S3–S9 (2003).
2. Bohn, M. & Kraemer, K. T. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J. Am. Acad. Dermatol. 43 Suppl, S57–S69 (2000).
3. Zhou, H. et al. The antitumor activity of the fungicide ciclopirox. Int. J. Cancer 127, 2467–2477 (2010).
4. Zhou, J. et al. CPX targeting DJ-1 triggers ros-induced cell death and protective autophagy in colorectal cancer. Theranostics 9, 5577–5594 (2019).
5. Braun, J. A. et al. Effects of the antifungal agent ciclopirox in HPV-positive cancer cells. Repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis. Int. J. Cancer 146, 461–474 (2009).
6. Mihalidou, C., Papakotoulas, P., Papavassiliou, A. G. & Karamouzis, M. V. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. Oncotarget 9, 10360–10374 (2018).
7. Qi, J. et al. Ciclopirox activates PERK-dependent endoplasmic reticulum stress to drive cell death in colorectal cancer. Cell Death Dis. 11, 582 (2020).
8. Minden, M. D. et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. Am. J. Hematol. 89, 363–368 (2014).
9. Bross, P. F. et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res. 10, 3954–3964 (2004). 12 Pt 1.
10. Cortes, J. et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 10, 3371–3376 (2004).
11. Horton, T. M. et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group Study. Clin. Cancer Res. 13, 1516–1522 (2007).
12. Messinger, Y. H. et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study. Blood 120, 285–290 (2012).
13. Wright, J. J. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin. Cancer Res. 16, 4094–4104 (2010).
14. Koyama, D. et al. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia 28, 1216–1226 (2014).
15. Huang, C. et al. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro. Cancer Chemother. Pharm. 70, 801–809 (2012).
16. Bastian, L. et al. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB. Clin. Cancer Res. 19, 1445–1457 (2013).
17. Li, Y. et al. Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling. Arch. Toxicol. 93, 3367–3383 (2019).
18. Comb, A., Bonnet, L. V., Goitea, V. E., Hallak, M. E. & Galiano, M. R. Arginylated calreticulin increases apoptotic response induced by bortezomib in glioma cells. Mol. Neurobiol. 56, 1653–1664 (2019).
19. Machtay, J. M. et al. Bortezomib, HIF-1α, and radiation therapy for glioblastoma: a phase II study. Clin. Cancer Res. 20, 1169–1181 (2013).
20. Lan, L. et al. Deferoxamine suppresses esophageal squamous cell carcinoma cell growth via ERK1/2 mediated mitochondrial dysfunction. Cancer Lett. 432, 132–143 (2018).
21. Chen, M. Y. et al. Preparation, characterization and in vitro-in vivo evaluation of bortezomib supermolecular aggregation nanovehicles. *J. Nanobiotechnol.* **18**, 57 (2020).

22. Jane, E. P., Premkumar, D. R. & Pollack, I. F. Bortezomib sensitizes malignant human glioma cells to TRAIL mediated by inhibition of the NF-κB signaling pathway. *Mol. Cancer Ther.* **10**, 198–208 (2011).

23. Xie, D. et al. Downregulation of TFAM inhibits the tumorigenesis of non-small cell lung cancer by activating ROS-mediated JNK/p38MAPK signaling and reducing cellular bioenergetics. *Oncotarget* **7**, 11609–11624 (2016).

24. Giridharan, S. & Srinivasan, M. Mechanisms of NF-κB p65 and strategies for therapeutic manipulation. *J. Inflamm. Res.* **11**, 407–419 (2018).

25. Aasland, D. et al. Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-κB. *Cancer Res.* **79**, 99–113 (2019).

26. Sahu, S. K. et al. FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development. *Nat. Commun.* **8**, 1523 (2017).

27. Radosky, E. S. & Radosky, D. C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. *J. Mammary Gland Biol. Neoplasia* **15**, 201–212 (2010).

28. Detaille, D., PasDOI, P., Sémont, A., Dos Santos, P. & Dolez, P. An old drug as a new drug to prevent mitochondrial complex I from producing oxygen radicals. *PloS One* **14**, e0216385–e0216385 (2019).

29. Munro, D. & Treberg, J. R. A radical shift in perspective: mitochondria as regulators of reactive oxygen species. *J. Exp. Biol.* **220**, 1170–1180 (2017).

30. Zanotto-Filho, A., Braganhol, E., Battistini, A. M. O. & Moreira, J. C. F. Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of P38/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling. *Invest N. Drugs* **30**, 2252–2262 (2012).

31. Yin, D. et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). *Oncogene* **24**, 344–354 (2005).

32. Vriend, J. & Reiter, R. J. The Keap1-NRF2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. *Mol. Cell Endocrinol.* **401**, 213–220 (2015).

33. Wagner, P. M. et al. Proliferative glioblastoma cancer cells exhibit persistent temporal control of metabolism and display differential temporal drug susceptibility in chemotherapy. *Mol. Neurobiol.* **56**, 1276–1292 (2019).

34. Bao, X. et al. Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma. *Int. J. Oncol.* **50**, 477–486 (2017).

35. Ockinghaus, A. & Ghosh, S. The NF-kappaB family of transcription factors and its regulation. *Cold Spring Harb. Perspect. Biol.* **1**, a000034–a000034 (2009).

36. Karin, M., Yamamoto, Y. & Wang, Q. M. The IKK NF-kappa B system: a treasure trove for drug development. *Nat. Rev. Drug Discov.* **3**, 17–26 (2004).

37. Pikarsky, E. & Ben-Neriah, Y. NF-kappaB inhibition: a double-edged sword in cancer? *Eur. J. Cancer* **42**, 779–784 (2006).

38. Baud, V. & Karin, M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. *Nat. Rev. Drug Discov.* **8**, 33–40 (2009).

39. Ryan, K. M., Ernst, M. K., Rice, N. R. & Vousden, K. H. Role of NF-kappaB in p53-mediated programmed cell death. *Nature* **404**, 892–897 (2000).

40. Coppé, J.-P., Desprez, P.-Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. *Annu. Rev. Pathol.* **5**, 99–118 (2010).

41. Wagner, P. M., Monjes, N. M. & Guido, M. E. Chemotherapeutic effect of SR9009, a REV-ERB agonist, on the human glioblastoma T98G cells. *ASN Neuro* **11**, 175909141982713 (2019).

42. Yao, Z. et al. Ursodeoxycholic acid inhibits glioblastoma progression via endoplasmic reticulum stress related apoptosis and synergizes with the proteasome inhibitor bortezomib. *ACS Chem. Neurosci.* **11**, 1337–1346 (2020).